NASDAQ:LYEL Lyell Immunopharma Q2 2024 Earnings Report $12.42 +2.01 (+19.31%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$12.46 +0.04 (+0.33%) As of 07/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Lyell Immunopharma EPS ResultsActual EPS-$3.60Consensus EPS -$4.00Beat/MissBeat by +$0.40One Year Ago EPSN/ALyell Immunopharma Revenue ResultsActual Revenue$0.01 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALyell Immunopharma Announcement DetailsQuarterQ2 2024Date8/7/2024TimeAfter Market ClosesConference Call DateWednesday, August 7, 2024Conference Call Time4:00PM ETUpcoming EarningsLyell Immunopharma's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Lyell Immunopharma Earnings HeadlinesLyell Immunopharma Shares Rise After Private Placement of Up to $100MJuly 25 at 5:44 PM | marketwatch.comLyell Immunopharma Announces up to $100 Million Equity Private PlacementJuly 25 at 8:00 AM | globenewswire.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.July 27 at 2:00 AM | American Alternative (Ad)Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program AdvancementJuly 23, 2025 | seekingalpha.comLyell Immunopharma, Inc. (LYEL) Balance Sheet - Yahoo FinanceJuly 15, 2025 | finance.yahoo.comLyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" SeriesJune 23, 2025 | tmcnet.comSee More Lyell Immunopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lyell Immunopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lyell Immunopharma and other key companies, straight to your email. Email Address About Lyell ImmunopharmaLyell Immunopharma (NASDAQ:LYEL), a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.View Lyell Immunopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?Why Freeport-McMoRan Stock May Hit a New High After Earnings BeatMicrosoft’s AI Bet Faces a Major Test This Earnings SeasonAmazon Stock Rally Hits New Highs: Buy Into Earnings?TSLA Earnings Week: Can Tesla Break Through $350?Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your Portfolio Upcoming Earnings Cadence Design Systems (7/28/2025)Enterprise Products Partners (7/28/2025)Welltower (7/28/2025)Waste Management (7/28/2025)AstraZeneca (7/29/2025)Booking (7/29/2025)Mondelez International (7/29/2025)PayPal (7/29/2025)Starbucks (7/29/2025)American Tower (7/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
